SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026
Globe Newswire•04/11/2026•08:41 ET
0
Key Highlights
- ➤Q3 financial results scheduled for November 11, 2026, after market close
- ➤QUELIMMUNE approved by FDA in 2024 for pediatric sepsis-related acute kidney injury
- ➤NEUTRALIZE-AKI pivotal trial evaluates SCD therapy in adults requiring continuous renal replacement therapy
- ➤SCD therapy has FDA Breakthrough Device Designation for seven therapeutic indications
DENVER, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Wednesday, November 11, 2026, and host a webcast and conference call to discuss its financial results and business progress.
Date/Time:Wednesday, November 11, 2026, at 4:30 p.m. ET / 2:30 p.m. MT
Get started
Create a free account to read the full story.